Log in

NASDAQ:KNSAKiniksa Pharmaceuticals News Headlines

$23.73
-1.80 (-7.05 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$23.25
Now: $23.73
$25.24
50-Day Range
$19.90
MA: $22.48
$26.00
52-Week Range
$5.01
Now: $23.73
$28.67
Volume398,358 shs
Average Volume338,746 shs
Market Capitalization$1.41 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.01

Headlines

Kiniksa Pharmaceuticals (NASDAQ KNSA) News Headlines

Source:
DateHeadline
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Downgraded by BidaskClub to HoldKiniksa Pharmaceuticals (NASDAQ:KNSA) Downgraded by BidaskClub to Hold
www.marketbeat.com - July 3 at 2:34 AM
Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) EVP Thomas W. Beetham Sells 29,589 SharesKiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) EVP Thomas W. Beetham Sells 29,589 Shares
www.marketbeat.com - July 2 at 5:47 PM
Kiniksa Pharmaceuticals Ltd Expected to Earn Q2 2020 Earnings of ($0.50) Per Share (NASDAQ:KNSA)Kiniksa Pharmaceuticals Ltd Expected to Earn Q2 2020 Earnings of ($0.50) Per Share (NASDAQ:KNSA)
www.americanbankingnews.com - July 2 at 7:45 AM
Kiniksa Pharmaceuticals Ltd to Post Q1 2021 Earnings of ($0.60) Per Share, Wedbush Forecasts (NASDAQ:KNSA)Kiniksa Pharmaceuticals Ltd to Post Q1 2021 Earnings of ($0.60) Per Share, Wedbush Forecasts (NASDAQ:KNSA)
www.americanbankingnews.com - July 1 at 8:36 AM
Kiniksas Heart Drug, And Other News: The Good, Bad, And Ugly Of BiopharmaKiniksa's Heart Drug, And Other News: The Good, Bad, And Ugly Of Biopharma
seekingalpha.com - June 30 at 3:48 PM
Goldman Sachs Group Raises Kiniksa Pharmaceuticals (NASDAQ:KNSA) Price Target to $33.00Goldman Sachs Group Raises Kiniksa Pharmaceuticals (NASDAQ:KNSA) Price Target to $33.00
www.americanbankingnews.com - June 30 at 12:02 PM
Company News for Jun 30, 2020Company News for Jun 30, 2020
finance.yahoo.com - June 30 at 10:47 AM
Zacks.com featured highlights include: eXp World, Lakeland Industries, Meridian Bioscience, Kiniksa Pharmaceuticals and iClick Interactive Asia GroupZacks.com featured highlights include: eXp World, Lakeland Industries, Meridian Bioscience, Kiniksa Pharmaceuticals and iClick Interactive Asia Group
finance.yahoo.com - June 30 at 10:47 AM
FDA Snubs HRTX Again, ICPT Disappoints, KNSA Hits Right Notes, Is The Writing On The Wall For VRCA?FDA Snubs HRTX Again, ICPT Disappoints, KNSA Hits Right Notes, Is The Writing On The Wall For VRCA?
www.nasdaq.com - June 30 at 5:47 AM
BofA Securities Boosts Kiniksa Pharmaceuticals (NASDAQ:KNSA) Price Target to $40.00BofA Securities Boosts Kiniksa Pharmaceuticals (NASDAQ:KNSA) Price Target to $40.00
www.americanbankingnews.com - June 29 at 2:30 PM
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Price Target Raised to $40.00 at BofA SecuritiesKiniksa Pharmaceuticals (NASDAQ:KNSA) Price Target Raised to $40.00 at BofA Securities
www.americanbankingnews.com - June 29 at 2:30 PM
Why Kiniksas Stock Is Trading Higher TodayWhy Kiniksa's Stock Is Trading Higher Today
www.benzinga.com - June 29 at 12:40 PM
Kiniksa Reports Positive Results of Pericarditis-Drug TrialKiniksa Reports Positive Results of Pericarditis-Drug Trial
finance.yahoo.com - June 29 at 12:40 PM
Kiniksa Pharmaceuticals (NASDAQ:KNSA) PT Raised to $38.00 at WedbushKiniksa Pharmaceuticals (NASDAQ:KNSA) PT Raised to $38.00 at Wedbush
www.americanbankingnews.com - June 29 at 11:52 AM
-$0.58 Earnings Per Share Expected for Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) This Quarter-$0.58 Earnings Per Share Expected for Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) This Quarter
www.americanbankingnews.com - June 27 at 9:14 PM
Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) Receives Consensus Recommendation of "Buy" from BrokeragesKiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - June 23 at 12:24 PM
Kiniksa Announces Lancet Rheumatology Publication of Clinical Outcomes with Mavrilimumab in COVID-19Kiniksa Announces Lancet Rheumatology Publication of Clinical Outcomes with Mavrilimumab in COVID-19
finance.yahoo.com - June 17 at 9:06 AM
Consonance Capital Management reports 11% stake in KiniksaConsonance Capital Management reports 11% stake in Kiniksa
seekingalpha.com - June 16 at 1:52 PM
Insider Selling: Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) EVP Sells 13,752 Shares of StockInsider Selling: Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) EVP Sells 13,752 Shares of Stock
www.americanbankingnews.com - June 15 at 4:16 AM
Zacks.com featured highlights include: SunOpta, eXp World, Calix, Kiniksa Pharmaceuticals and iClick Interactive Asia GroupZacks.com featured highlights include: SunOpta, eXp World, Calix, Kiniksa Pharmaceuticals and iClick Interactive Asia Group
finance.yahoo.com - June 12 at 12:27 PM
Kiniksa Provides Timing of Second Half 2020 Clinical Data ReadoutsKiniksa Provides Timing of Second Half 2020 Clinical Data Readouts
finance.yahoo.com - June 10 at 12:49 PM
Kiniksa Positive COVID-19 Data And Other News: The Good, Bad And Ugly Of BiopharmaKiniksa Positive COVID-19 Data And Other News: The Good, Bad And Ugly Of Biopharma
seekingalpha.com - June 10 at 7:48 AM
Kiniksas mavrilimumab shows encouraging effect in COVID patientsKiniksa's mavrilimumab shows encouraging effect in COVID patients
seekingalpha.com - June 8 at 11:46 AM
Kiniksa Announces 28-Day Clinical Outcomes Data from Mavrilimumab Treatment Protocol in Severe COVID-19 Pneumonia and Active U.S. IND for Phase 2/3 Clinical TrialKiniksa Announces 28-Day Clinical Outcomes Data from Mavrilimumab Treatment Protocol in Severe COVID-19 Pneumonia and Active U.S. IND for Phase 2/3 Clinical Trial
finance.yahoo.com - June 8 at 11:46 AM
Kiniksa Pharmaceuticals to Present at 41st Annual Goldman Sachs Global Healthcare ConferenceKiniksa Pharmaceuticals to Present at 41st Annual Goldman Sachs Global Healthcare Conference
finance.yahoo.com - June 4 at 9:40 AM
BRIEF-Kiniksa Pharmaceuticals Files For Offering Of Up To 1.6 Mln Class A Common SharesBRIEF-Kiniksa Pharmaceuticals Files For Offering Of Up To 1.6 Mln Class A Common Shares
www.reuters.com - May 22 at 1:51 PM
How Kiniksa Pharmaceuticals (KNSA) Stock Stands Out in a Strong IndustryHow Kiniksa Pharmaceuticals (KNSA) Stock Stands Out in a Strong Industry
finance.yahoo.com - May 22 at 1:51 PM
Kiniksa Pharmaceuticals, Ltd. Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional SharesKiniksa Pharmaceuticals, Ltd. Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
www.marketwatch.com - May 18 at 6:13 PM
Kiniksa Pharmaceuticals, Ltd. Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesKiniksa Pharmaceuticals, Ltd. Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - May 18 at 6:13 PM
Kiniksa Pharmaceuticals prices equity offering, Shares down 5%Kiniksa Pharmaceuticals prices equity offering, Shares down 5%
seekingalpha.com - May 14 at 1:59 AM
Kiniksa Pharmaceuticals, Ltd. Announces Proposed Public OfferingKiniksa Pharmaceuticals, Ltd. Announces Proposed Public Offering
finance.yahoo.com - May 13 at 8:58 PM
Which way to trade Kiniksa Pharmaceuticals (NSQ:KNSA)?Which way to trade Kiniksa Pharmaceuticals (NSQ:KNSA)?
uk.finance.yahoo.com - May 13 at 9:52 AM
Kiniksas mavrilimumab shows positive effect in severely-ill COVID patientsKiniksa's mavrilimumab shows positive effect in severely-ill COVID patients
seekingalpha.com - May 11 at 3:19 PM
Kiniksa Reports Data for Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation and for Vixarelimab in Diseases Characterized by Chronic PruritusKiniksa Reports Data for Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation and for Vixarelimab in Diseases Characterized by Chronic Pruritus
finance.yahoo.com - May 11 at 10:17 AM
Will Kiniksa Pharmaceuticals Continue to Surge Higher?Will Kiniksa Pharmaceuticals Continue to Surge Higher?
finance.yahoo.com - May 6 at 6:06 PM
Kiniksa Pharmaceuticals EPS beats by $0.13Kiniksa Pharmaceuticals EPS beats by $0.13
seekingalpha.com - April 28 at 11:23 AM
Kiniksas vixarelimab successful in lumpy skin diseaseKiniksa's vixarelimab successful in lumpy skin disease
seekingalpha.com - April 22 at 1:57 PM
Kiniksa Announces Phase 2 Clinical Trial of Vixarelimab (KPL-716) in Prurigo Nodularis Meets Primary Efficacy EndpointKiniksa Announces Phase 2 Clinical Trial of Vixarelimab (KPL-716) in Prurigo Nodularis Meets Primary Efficacy Endpoint
finance.yahoo.com - April 22 at 8:57 AM
Kiniksas Unexpected PlayKiniksa's Unexpected Play
seekingalpha.com - April 11 at 2:14 AM
Has Kiniksa Pharmaceuticals (KNSA) Outpaced Other Medical Stocks This Year?Has Kiniksa Pharmaceuticals (KNSA) Outpaced Other Medical Stocks This Year?
finance.yahoo.com - April 8 at 12:31 PM
Vaccine for COVID-19 Health Crises "Possible" by Summer After FDA Fast-Tracks Clinical TrialsVaccine for COVID-19 Health Crises "Possible" by Summer After FDA Fast-Tracks Clinical Trials
www.prnewswire.com - April 1 at 4:01 PM
Stock Alert: Kiniksa Pharma Gains 20%Stock Alert: Kiniksa Pharma Gains 20%
www.nasdaq.com - March 31 at 12:16 PM
Kiniksa Pharmas mavrilimumab shows treatment response in COVID-19 patients; shares up 39% premarketKiniksa Pharma's mavrilimumab shows treatment response in COVID-19 patients; shares up 39% premarket
seekingalpha.com - March 31 at 12:16 PM
Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab in 6 Patients with Severe COVID-19 Pneumonia and HyperinflammationKiniksa Announces Early Evidence of Treatment Response with Mavrilimumab in 6 Patients with Severe COVID-19 Pneumonia and Hyperinflammation
finance.yahoo.com - March 31 at 12:16 PM
Kiniksa Highlights Phase 2 Study Data Showing the...Kiniksa Highlights Phase 2 Study Data Showing the...
www.benzinga.com - March 30 at 9:02 PM
Kiniksa Highlights Phase 2 Study Data Showing the Corticosteroid-Sparing Effect of Rilonacept in Patients with Recurrent Pericarditis at the American College of Cardiologys 69th Annual Scientific SessionKiniksa Highlights Phase 2 Study Data Showing the Corticosteroid-Sparing Effect of Rilonacept in Patients with Recurrent Pericarditis at the American College of Cardiology's 69th Annual Scientific Session
finance.yahoo.com - March 30 at 9:02 PM
Gilead's BLA for CAR T Cell Therapy Gets FDA AcceptanceGilead's BLA for CAR T Cell Therapy Gets FDA Acceptance
finance.yahoo.com - February 11 at 2:15 PM
BRIEF-Kiniksa Pharmaceuticals says CFO Chris Heberlig, Agreed That He Will Transition To A Consulting Role With Co On March 20BRIEF-Kiniksa Pharmaceuticals says CFO Chris Heberlig, Agreed That He Will Transition To A Consulting Role With Co On March 20
www.msn.com - February 5 at 7:50 PM
Kiniksa Announces Pipeline Progress and Reiterates 2020 Clinical Data ReadoutsKiniksa Announces Pipeline Progress and Reiterates 2020 Clinical Data Readouts
finance.yahoo.com - January 13 at 1:32 PM
Did Hedge Funds Drop The Ball On Kiniksa Pharmaceuticals, Ltd. (KNSA) ?Did Hedge Funds Drop The Ball On Kiniksa Pharmaceuticals, Ltd. (KNSA) ?
finance.yahoo.com - December 16 at 8:55 AM
This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.